GeneBio Systems

ADMA ELISA kit (General species)

Name: ADMA ELISA kit (General species)
Brand: GeneBio Systems
SKU: CEB301Ge
Price: 1696.80 CAD
Availability: InStock

SKU:CEB301Ge

$1,696.80 CAD

Sale Sold out

Shipping calculated at checkout.

Quantity

Size: 96Tests

# of Times Cited in literature: 29

Prepare Time: 1-3 days(please inquire for mutiple units)

Target Name: ADMA

Target Full Name: Asymmetrical Dimethylarginine

Alternative Names: N,N-Dimethylarginine; NG,NG-Dimethylarginine dihydrochloride; Asymmetric Dimethylarginine

Target Species: General species

Uniprot: -

Gene ID: -

Featured Series: CE kit

Featured Series Function: Detects small molecule

Specificity: Reactive with General species ADMA / Asymmetrical Dimethylarginine

Method: Colormetric

Detection principle: Competitive Inhibition

Detection range: 12.35-1,000ng/mL

Sensitivity: 4.99ng/mL

Assay Time: 2h

Sample Size: 50uL

Recommended/Predicted Sample Types: Serum, Plasma, Tissue Homogenates, Cell Lysates, Cell Culture Supernates and other Biological Fluids

Assay Precision: Intra-Assay: CV<10%, Inter-Assay: CV<12%

Reproducibility test menthod: Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Asymmetrical Dimethylarginine (ADMA) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Asymmetrical Dimethylarginine (ADMA) were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100

Storage: 4°C for 1 month/ -20°C for long-term(One year within shelf life)

Shelf-life: 12 months

Specificity: This assay has high sensitivity and excellent specificity for detection of Asymmetrical Dimethylarginine (ADMA). No significant cross-reactivity or interference between Asymmetrical Dimethylarginine (ADMA) and analogues was observed.

Stability: The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Assay procedure summary: 1. Prepare all reagents, samples and standards; 2. Add 50µL standard or sample to each well. And then add 50µL prepared Detection Reagent A immediately. Shake and mix. Incubate 1 hour at 37°C; 3. Aspirate and wash 3 times; 4. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C; 5. Aspirate and wash 5 times; 6. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C; 7. Add 50µL Stop Solution. Read at 450 nm immediately.

Test principle: This assay employs the competitive inhibition enzyme immunoassay technique. A monoclonal antibody specific to Asymmetrical Dimethylarginine (ADMA) has been pre-coated onto a microplate. A competitive inhibition reaction is launched between biotin labeled Asymmetrical Dimethylarginine (ADMA) and unlabeled Asymmetrical Dimethylarginine (ADMA) (Standards or samples) with the pre-coated antibody specific to Asymmetrical Dimethylarginine (ADMA). After incubation the unbound conjugate is washed off. Next, avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. The amount of bound HRP conjugate is reverse proportional to the concentration of Asymmetrical Dimethylarginine (ADMA) in the sample. After addition of the substrate solution, the intensity of color developed is reverse proportional to the concentration of Asymmetrical Dimethylarginine (ADMA) in the sample.

Research Area: Metabolic pathway;Cardiovascular biology;

References Citing This Product: Interactions among Vascular-Tone Modulators Contribute to High Altitude Pulmonary Edema and Augmented Vasoreactivity in Highlanders

Effect of CCL5 on dimethylarginine dimethylaminohydrolase-1 production in vascular smooth muscle cells from spontaneously hypertensive rats.

Effect of 18β-glycyrrhetinic acid on cerebral vasospasm caused by asymmetric dimethylarginine after experimental subarachnoid hemorrhage in rats.

Correlation research on ADMA plasma levels and left ventricular function of peritoneal dialysis patients

Asymmetric dimethylarginine contributes to airway nitric oxide deficiency in patients with COPD

Dimethylarginine dimethylaminohydrolase-1 mediates inhibitory effect of interleukin-10 on angiotensin II-induced hypertensive effects in vascular smooth muscle cells of spontaneously hypertensive rats

Effect of 18β-glycyrrhetinic acid on cerebral vasospasm caused by asymmetric dimethylarginine after experimental subarachnoid hemorrhage in rats

Dimethylarginine Dimethylaminohydrolase 2 (DDAH 2) Gene Polymorphism, Asymmetric Dimethylarginine (ADMA) Concentrations, and Risk of Coronary Artery Disease: A Case-Control Study

Increased serum concentrations of asymmetric dimethylarginine (ADMA) in patients with early-onset coronary artery disease.

Asymmetric dimethylarginine (ADMA) elevation and arginase up-regulation contribute toendothelial dysfunction related to insulin resistance in rats and morbidly obese humans.

Dimethylarginine dimethylaminohydrolase-1 (DDAH1) is frequently upregulated in prostate cancer, and its overexpression conveys tumor growth and angiogenesis by metabolizing asymmetric dimethylarginine (ADMA).